BlackBerry Overview - BlackBerry has 3 divisions: QNX, Secure Communications, and Licensing[12] - The company's 2025 revenue was approximately $532 million[12] - BlackBerry has significantly enhanced its cash flow profile, with operating cash flow increasing from -$262 million in FY23 to $17 million in FY25[12] - BlackBerry's QNX is on a path to a "Rule of 40" division[50] QNX Performance and Market - QNX is a leader in automotive and other embedded systems[15] - QNX is experiencing double-digit revenue growth[15] - QNX's serviceable addressable market (SAM) is projected to grow from $1.8 billion in CY2024 to $2.9 billion in CY2028, with a core CAGR of approximately 8-14%[18] - QNX total CAGR is projected to be ~34% from '24 to '28[18] - QNX royalty backlog was up to $865 million in Q4 FY'25, compared to $460 million in Q4 FY'22[50] Strategic Initiatives - BlackBerry is focused on solution innovation, including product and technology bundles and flexible pricing strategies[35] - BlackBerry is strategically collaborating with Vector to transform the traditional automotive value chain[36] - BlackBerry is expanding QNX access to more developers through the QNX Everywhere program, with over 12,000 SDP 8.0 licenses deployed for non-commercial use[48]

Financial Performance and Growth - The company's Utilities segment revenue reached $2.658 billion in TTM Q3 2025[9], while the Energy segment revenue was $4.931 billion in TTM Q3 2025[12, 19] - The company's backlog for Utilities was $6.593 billion in Q3 2025[15], and for Energy was $4.470 billion in Q3 2025[20] - The company targets a gross profit growth of 9% to 12%[38, 84] - The company projects full year 2025 Adjusted EBITDA to be between $510 million and $530 million[88, 98] - The company anticipates full year 2025 Adjusted EPS to be in the range of $5.35 to $5.55 per diluted share[88, 96] Strategic Focus and Market Positioning - The company is focused on high-growth markets like Renewables and Power Delivery[38, 41] - The company aims to grow solar revenue from $1.3 billion in 2023 to $2.9 billion in TTM Q3 2025[63] - The company is targeting an operating cash flow margin of 4% to 5% by 2026[84] - The company is aiming for a Net Debt / Adjusted EBITDA target of 1.5x[68, 84] Contract and Customer Base - Reimbursable contracts account for 51% of revenue, while fixed-price contracts account for 49% in TTM Q3 2025[25] - The company derives 41% of its revenue from its top 10 customers[33]

Financial Performance - Q3 FY26 - Net sales increased by 2.1% year-over-year (YoY) to $348.6 million[12, 13] - Adjusted EBITDA increased by 0.7% YoY to $46.1 million[12, 13] - Adjusted EBITDA margin decreased by 20 basis points (bps) YoY to 13.2%[12, 13] - Adjusted diluted EPS decreased by 14.3% YoY to $1.02[12, 13] Segment Performance - Q3 FY26 - Architectural Metals net sales decreased by 9.9% YoY to $124.4 million[23] - Architectural Services net sales increased by 0.2% YoY to $105.2 million[23] - Architectural Glass net sales increased by 0.9% YoY to $70.9 million[23] - Performance Surfaces net sales increased by 59.6% YoY to $53.0 million[23] Cash Flow and Debt - Free cash flow for the nine months ended November 29, 2025, was $48.3 million, compared to $70.4 million for the same period in the previous year[27] - Total debt as of November 29, 2025, was $255.0 million, down from $285.0 million as of March 1, 2025[27] FY26 Outlook - The company updated its full-year FY26 net sales outlook to approximately $1.39 billion (previously $1.39 billion - $1.42 billion)[41] - The company updated its full-year FY26 adjusted diluted EPS outlook to $3.40 - $3.50 (previously $3.60 - $3.90)[41] - Tariffs are estimated to reduce full-year adjusted diluted EPS by $0.30[45]

Financial Performance - Cal-Maine Foods' net sales for Q2 FY26 were $769.5 million, a decrease of 19.4%[8] - Gross profit for Q2 FY26 was $207.4 million, down 41.8%[8] - Operating income for Q2 FY26 was $123.9 million, a decrease of 55.5%[8] - Net income attributable to Cal-Maine for Q2 FY26 was $102.8 million, down 53.1%[8] - Diluted EPS for Q2 FY26 was $2.13, a decrease of 52.3%[8] - Net cash flow from operations for Q2 FY26 was $94.8 million, down 22.8%[8] Strategic Growth & Diversification - Specialty eggs and prepared foods accounted for 46% of net sales in Q2 FY26, an increase from 31% in Q2 FY25[10, 11] - Specialty eggs represented 44% of shell egg sales in Q2 FY26, up from 32% in Q2 FY25[13, 15] - The company is investing to expand prepared foods capabilities, expecting to add 17 million pounds annually of scrambled egg production by mid-fiscal 2027[17] - A high-speed pancake line is expected to add another 12 million pounds of capacity through early fiscal 2027[17] - Crepini Foods is investing to add 18 million pounds of capacity, expanding production more than sevenfold[17] Capital Allocation - Cal-Maine repurchased 846,037 shares of its common stock during the quarter for a total of $74.8 million[23]

BBO-8520 (KRASG12C Inhibitor) - BBO-8520 demonstrated encouraging efficacy, safety, and early durability data in monotherapy [80] - In monotherapy, BBO-8520 achieved a 65% ORR (11/17 patients) and a 100% DCR (17/17 patients) in previously treated KRASG12C NSCLC patients [21] - 83% of patients eligible for 6-month follow-up remained on treatment for at least 6 months, with a 6-month PFS of 66% [23, 27] - BBO-8520 in combination with pembrolizumab showed early efficacy data and a distinct tolerable safety profile [80] - In combination with pembrolizumab, the TRAE rate was 47% (7/15 patients), with a Grade ≥3 TRAE rate of 13% (2/15 patients) [33] - Early efficacy signals were observed in resistant STK11/KEAP1 co-mutants [45, 80] BBO-11818 (panKRAS Inhibitor) - BBO-11818 demonstrated a partial response (PR) in a patient with pancreatic cancer [6, 56, 80] - BBO-11818 showed anti-tumor activity across dose levels and tumor types with tumor reductions at higher dose levels [7, 55, 80] - The company observed a differentiated safety profile in dose escalation [7, 80] BBO-10203 (RAS:PI3Kα Breaker) - BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on HbA1c levels [7, 80] - BBO-10203 monotherapy DCR was 62% (13/21 patients) [76]

Fiscal First Quarter 2026 Performance - Average daily sales ("ADS") increased by 4% year-over-year, aligning with the midpoint of the company's outlook[6] - Gross margin was 40.7%, meeting the midpoint of the projected range[6] - Reported earnings per share (EPS) was $0.93, while adjusted EPS reached $0.99, representing year-over-year increases of 12% and 15%, respectively[6] - Reported operating margin increased by 10 bps year-over-year, and adjusted operating margin rose by 40 bps year-over-year, surpassing the midpoint of the outlook[6] - The company returned approximately $62 million to shareholders through dividends and share repurchases[6] Segment and Initiative Performance - Core Customers' ADS grew by approximately 6% year-over-year, outperforming the total company's growth for the second consecutive quarter[13] - National Accounts returned to growth, with ADS improving by approximately 3% year-over-year[13] - Sales from In-Plant programs increased by 13% year-over-year, accounting for 20% of total sales[29] - Sales through vending machines grew by 9% year-over-year, representing 19% of total sales[29] Balance Sheet and Cash Flow - Free cash flow decreased year-over-year, resulting in a free cash flow conversion of 14%[31] - Net debt increased by $28 million due to higher debt levels and lower cash on hand[31] - The company maintains a healthy balance sheet, with a net debt to EBITDA ratio of 1.2x[31] Second Quarter 2026 Outlook - The company expects ADS to increase by 3.5% to 5.5% year-over-year[40] - Adjusted operating margin is projected to be between 7.3% and 7.9%[40]

Financial Performance - Sales increased by 16% from Q2 FY25 to Q2 FY26[9] - Adjusted EBITDA increased by 23% from Q2 FY25 to Q2 FY26[9] - Adjusted EPS increased by 31% from Q2 FY25 to Q2 FY26[9] - Parts Supply sales increased by 29% from Q2 FY25 to Q2 FY26[28] - Integrated Solutions sales increased by 8% from Q2 FY25 to Q2 FY26[38] - Adjusted operating margin increased from 92% to 102%[24] Acquisitions and Strategic Initiatives - Acquired ADI, a distributor of electronic components and assemblies, with $149 million in sales and $15 million in EBITDA[9, 13] - Acquired HAECO Americas, the 2nd largest independent North American heavy maintenance provider, securing $850 million+ in new multi-year contracts[9, 15] - Announced an agreement to acquire Aircraft Reconfig Technologies for $35 million[9, 20] Balance Sheet and Leverage - Net leverage decreased by 109x since the Product Support acquisition[41] - The company is targeting a net leverage ratio of 20x – 25x[42, 46] Guidance - Q3 FY26 total sales growth is projected to be 20%-22%, with organic sales growth of 8%-11%[53]

Financial Performance - Penguin Solutions' net sales for Q1 FY26 were $343 million, a 1% increase year-over-year (YoY)[10] - The non-GAAP gross margin was 30.0%, a decrease of 0.8 percentage points YoY[10] - Non-GAAP operating income reached $42 million, up 1% YoY, with a non-GAAP operating margin of 12.1%, up 0.1 percentage points YoY[10] - Non-GAAP diluted earnings per share (EPS) remained flat YoY at $0.49[10] Segment Performance - Advanced Computing net sales were $151 million in Q1, up 9% compared to Q4 FY25[25] - Integrated Memory revenue was $137 million in Q1, a significant increase of 41% YoY[27] - Optimized LED net sales were $55 million in Q1, down 18% YoY, but achieved an operating income of $3.5 million, up 24% sequentially[30] Balance Sheet and Cash Flow - Net accounts receivable stood at $342 million[43] - Inventory was valued at $213 million[43] - Cash, cash equivalents, and short-term investments totaled $461 million at the end of the period[43] - Net cash from operating activities from continuing operations was $31 million[43] Stock Repurchase - Penguin Solutions repurchased 791,000 shares for $15 million in Q1 FY26[46] - Since April 2022, the company has repurchased 7.4 million shares for a total of $128 million[46] FY26 Outlook - Penguin Solutions anticipates net sales growth of 6% YoY, with a potential variance of +/- 10%[48] - The projected gross margin is 29% +/- 1%[48] - Operating expenses are expected to be $250 million +/- $10 million on a non-GAAP basis[48] - Non-GAAP diluted earnings per share are forecasted at $2.00 +/- $0.25[48]

ARO-INHBE Clinical Data - ARO-INHBE achieved a mean maximum reduction of 85% in serum Activin E after a single 400 mg dose, with a maximum observed reduction of 94%[80, 147] - ARO-INHBE monotherapy reduced visceral fat by 9.9% after a single dose at week 16 and 15.6% after two doses at week 24[82, 85, 147] - In obese diabetic patients, ARO-INHBE combined with tirzepatide doubled weight loss compared to tirzepatide alone, showing a 9.4% weight loss at week 16 versus 4.8% with tirzepatide alone[103, 105, 147] - Combination therapy with ARO-INHBE and tirzepatide in obese diabetic patients resulted in a 23.2% reduction in visceral fat, a 15.4% reduction in total fat, and a 76.7% reduction in liver fat, approximately a 3-fold improvement compared to tirzepatide alone across these measures[106, 107, 148] ARO-ALK7 Clinical Data - ARO-ALK7 demonstrated a mean reduction of 88% in ALK7 mRNA, confirming the TRiM platform's ability to silence adipocyte gene expression, with a maximum reduction of 94%[135, 148] - ARO-ALK7 showed a rapid dose-dependent reduction in visceral fat of up to 14% (placebo-adjusted) after a single dose[137, 148] General Summary - Both ARO-INHBE and ARO-ALK7 demonstrated favorable safety profiles in their respective monotherapy and combination therapy trials[113, 139] - The company plans to initiate Phase 2b studies as soon as possible and expand the obesity pipeline with new targets, including dimers[151] - Arrowhead's growth drivers in 2026 and beyond include potential multi-billion-dollar opportunity from Phase 3 studies of plozasiran in severe hypertriglyceridemia, first clinical readout of ARO-DIMER-PA targeting PCSK9 and APOC3 in 2H 2026, and emerging CNS pipeline with systemic delivery via SC administration[155]

Strategic Partnership with TPG - TPG will acquire approximately 6.5% common equity stake in JFI at $106.03 per share, totaling $500 million at close[7] - Jackson will receive $150 million of TPG common equity at $65.82 per share[7] - TPG's AUM managed by TPG needs to reach $4 billion by the end of year 2 and $12 billion by the end of year 5[7] - TPG is a leading global alternative asset management firm with $286 billion of AUM[12] Formation of Hickory Re - Hickory Re is a Michigan-based captive reinsurer 100% owned by Brooke Re[18] - Hickory Re will reinsure new FA and FIA sales, initially reinsuring $1.2 billion inforce FA/FIA block[18] - Initial capitalization of Hickory Re is $650 million, including $150 million from JFI and $500 million from TPG investment in JFI common equity[10, 18] Financial Impact and Outlook - Expect capital capacity and efficiency to write $10-15 billion of cumulative FA and FIA sales over the medium-term[23] - Actuarial assumption review is expected to have an after-tax impact to Brooke Re equity of approximately $(350) million[26] - Brooke Re continues to be well capitalized relative to regulatory requirements[26]